Israel mRNA Vaccines and RNAi Therapeutics Market (2025-2031) | Segmentation, Share, Competitive Landscape, Growth, Value, Industry, Trends, Analysis, Outlook, Size & Revenue, Companies, Forecast

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3.1 Israel Country Macro Economic Indicators

3.2 Israel mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, 2021 & 2031F

3.3 Israel mRNA Vaccines and RNAi Therapeutics Market - Industry Life Cycle

3.4 Israel mRNA Vaccines and RNAi Therapeutics Market - Porter's Five Forces

3.5 Israel mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume Share, By Disease Type, 2021 & 2031F

3.6 Israel mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume Share, By Administration, 2021 & 2031F

3.7 Israel mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume Share, By End user, 2021 & 2031F

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing research and development activities in mRNA vaccines and RNAi therapeutics in Israel

4.2.2 Growing investment in healthcare infrastructure and biotechnology sector

4.2.3 Rising prevalence of chronic diseases driving the demand for innovative treatments

4.3 Market Restraints

4.3.1 Stringent regulatory requirements and approval processes for mRNA vaccines and RNAi therapeutics

4.3.2 Limited awareness and acceptance of mRNA vaccines and RNAi therapeutics among healthcare professionals and patients

6.1 Israel mRNA Vaccines and RNAi Therapeutics Market, By Disease Type

6.1.1 Overview and Analysis

6.1.2 Israel mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Disease Type, 2021- 2031F

6.1.3 Israel mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Hereditary transthyretin-mediated amyloidosis genetic, 2021- 2031F

6.1.4 Israel mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Acute hepatic porphyria, 2021- 2031F

6.1.5 Israel mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Primary hyperoxaluria type 1, 2021- 2031F

6.1.6 Israel mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Atherosclerotic cardiovascular disease, 2021- 2031F

6.2 Israel mRNA Vaccines and RNAi Therapeutics Market, By Administration

6.2.1 Overview and Analysis

6.2.2 Israel mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By IV infusion, 2021- 2031F

6.2.3 Israel mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Subcutaneous, 2021- 2031F

6.3 Israel mRNA Vaccines and RNAi Therapeutics Market, By End user

6.3.1 Overview and Analysis

6.3.2 Israel mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Research Institutes, 2021- 2031F

6.3.3 Israel mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Hospitals and Clinics, 2021- 2031F

7.1 Israel mRNA Vaccines and RNAi Therapeutics Market Export to Major Countries

7.2 Israel mRNA Vaccines and RNAi Therapeutics Market Imports from Major Countries

8.1 Research and development expenditure in mRNA vaccines and RNAi therapeutics

8.2 Number of clinical trials conducted for mRNA vaccines and RNAi therapeutics in Israel

8.3 Adoption rate of mRNA vaccines and RNAi therapeutics by healthcare institutions and practitioners

9.1 Israel mRNA Vaccines and RNAi Therapeutics Market Opportunity Assessment, By Disease Type, 2021 & 2031F

9.2 Israel mRNA Vaccines and RNAi Therapeutics Market Opportunity Assessment, By Administration, 2021 & 2031F

9.3 Israel mRNA Vaccines and RNAi Therapeutics Market Opportunity Assessment, By End user, 2021 & 2031F

10.1 Israel mRNA Vaccines and RNAi Therapeutics Market Revenue Share, By Companies, 2024

10.2 Israel mRNA Vaccines and RNAi Therapeutics Market Competitive Benchmarking, By Operating and Technical Parameters